跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/CTRI/2021/05/033375
CTRI/2021/05/033375招募中4 期

An open label, multi-center, Phase IV rollover protocol for patientswho have completed a prior global Novartis or Incyte sponsoredruxolitinib (INC424) study or ruxolitinib and panobinostat (LBH589)combination study, and are judged by the investigator to benefitfrom continued treatment

ovartis Healthcare Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
4 期
状态
招募中
发起方
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • •Patient is currently enrolled in a Novartis-sponsored Global Drug
  • •Development (GDD) or Global Medical Affairs (GMA) study or
  • •Incyte-sponsored study (where Incyte can delegate the sponsorship
  • •to a preferred CRO, if applicable) that is approved to enroll into
  • •this rollover study, and are receiving either ruxolitinib or
  • •combination of ruxolitinib and panobinostat, and fulfilled all of the
  • •requirements of the parent protocol.
  • •Patient is currently benefiting from the treatment with ruxolitinib
  • •monotherapy or combination of ruxolitinib and panobinostat, as
  • •determined by the investigator.

排除标准

  • •Patient has been permanently discontinued from study treatment in
  • •the parent study due to any reason.
  • •Patient’s indication is currently approved and reimbursed in the
  • •local country for ruxolitinib monotherapy or other study drugs in
  • •the combination treatment (panobinostat).

研究者

发起方
ovartis Healthcare Pvt Ltd

相似试验

招募中
4 期
An open label, multi-center, Phase IV rollover protocol to evaluate long term safety dataindications including but not limited to myelofibrosis (MF), polycythemia vera (PV), acute Graft vs Host Disease (aGvHD) or chronic Graft vs Host Disease (cGvHD).
JPRN-jRCT2080225007ovartis Pharma. K.K.356
进行中（未招募）
1 期
A study for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study or ruxolitinib and panobinostat (LBH589) combination study and are judged by the investigator to benefit from continued treatmentThis roll-over study is designed to accept patients with varied disease origins. Please refer to the parent protocol for the disease background information and rationale for use of ruxolitinib in their individual indications.MedDRA version: 21.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10074692Term: Post essential thrombocythaemia myelofibrosisSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10036061Term: Polycythemia veraSystem Organ Class: 100000004864MedDRA version: 20.1Level: LLTClassification code 10054658Term: ThalassemiaSystem Organ Class: 100000004850MedDRA version: 20.1Level: PTClassification code 10066264Term: Acute graft versus host disease in intestineSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066262Term: Acute graft versus host disease in skinSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066263Term: Acute graft versus host disease in liverSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066260Term: Acute graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066261Term: Chronic graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10072160Term: Chronic graft versus host disease in liverSystem Organ
EUCTR2014-003527-22-PLovartis Pharma Services AG366
进行中（未招募）
1 期
A study for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study or a study of ruxolitinib in combination with panobinostat (LBH589) or siremadlin (HDM201) or rineterkib (LTT462) and are judged by the investigator to benefit from continued treatment
EUCTR2014-003527-22-DEovartis Pharma Services AG366
进行中（未招募）
1 期
A study for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study or ruxolitinib and panobinostat (LBH589) combination study and are judged by the investigator to benefit from continued treatment
EUCTR2014-003527-22-PTovartis Pharma Services AG366
进行中（未招募）
1 期
A study for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study or ruxolitinib and panobinostat (LBH589) combination study and are judged by the investigator to benefit from continued treatmentThis roll-over study is designed to accept patients with varied disease origins. Please refer to the parent protocol for the disease background information and rationale for use of ruxolitinib in their individual indications.MedDRA version: 21.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10074692Term: Post essential thrombocythaemia myelofibrosisSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10036061Term: Polycythemia veraSystem Organ Class: 100000004864MedDRA version: 20.1Level: LLTClassification code 10054658Term: ThalassemiaSystem Organ Class: 100000004850MedDRA version: 20.1Level: PTClassification code 10066264Term: Acute graft versus host disease in intestineSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066262Term: Acute graft versus host disease in skinSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066263Term: Acute graft versus host disease in liverSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066260Term: Acute graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066261Term: Chronic graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10072160Term: Chronic graft versus host disease in liverSystem Organ
EUCTR2014-003527-22-BGovartis Pharma Services AG366